IP Library Granted Patent US 7,718,640
Granted Patent B2
US 7,718,640 · App. 10/798,780 · Granted May 18, 2010

Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,640
App. No.
10/798,780
Granted
May 18, 2010
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.

Claims (14)

1. A composition formulated for intramuscular injection in a form for single injection which contains 250 mg/ml testosterone undecanoate in a vehicle containing a mixture of castor oil and benzyl benzoate wherein the vehicle contains castor oil in a concentration of 40 to 42 vol %.

2. A composition formulated for intramuscular injection in a form for single injection according to claim 1 , which contains 750 mg testosterone undecanoate.

3. The composition according to claim 1 , which contains 1000 mg of testosterone undecanoate.

4. The composition according to claim 2 , wherein the vehicle comprises the castor oil in a concentration of 25 to 30 vol %.

5. The composition according to claim 1 , wherein the benzyl benzoate is in an amount of 55 to 65 vol % in the composition.

6. The composition of claim 1 , wherein the vehicle consists of castor oil and benzyl benzoate.

7. The composition of claim 2 , wherein the vehicle consists of castor oil and benzyl benzoate.

8. A composition formulated for intramuscular injection in a form for single injection which contains 250 mg/ml testosterone undecanoate in a vehicle containing a mixture of castor oil and benzyl benzoate, wherein the vehicle contains the castor oil in a concentration of about 40 vol %.

9. A composition according to claim 8 , which contains 750 mg testosterone undecanoate.

10. The composition according to claim 8 , which contains 1000 mg of testosterone undecanoate.

11. The composition of claim 8 , wherein the composition contains no plant oil other than castor oil.

12. The composition of claim 9 , wherein the composition contains no plant oil other than castor oil.

13. The composition of claim 8 , wherein the vehicle consists of castor oil and benzyl benzoate.

14. The composition of claim 9 , wherein the vehicle consists of castor oil and benzyl benzoate.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: BAYER INTELLECTUAL PROPERTY GMBH
To: GRÜNENTHAL GMBH
Reel/Frame 062448/0602 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
PREVIOUSLY RECORDED ASSIGNMENT (ON 11/28/2012-029373/0170) CONTAINED THE ENGLISH LANGUAGE TRANSLATION OF THE COMMERCIAL REGISTER. THE GERMAN VERSION OF THE COMMERCIAL REGISTER, ENGLISH TRANSLATION AND TRANSLATOR CERTIFICATE NOW SUBMITTED. Recorded Apr 29, 2014
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 032796/0029 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
GRANT OF SECURITY INTEREST IN LICENSED PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0620 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
CHANGE OF NAME Recorded Nov 28, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029373/0170 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Feb 13, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023928/0628 →